6-chloro-N-(2-morpholin-4-ylethyl)-1,3-benzothiazol-2-amine, 95.0%, 250mg

5-(3,4-dichlorophenyl)-1H-pyrazole, 95.0%, 250mg

Ethyl 1H-indole-3-carboxylate, 95.0%, 25g

2-Bromo-4-fluoro-6-nitrotoluene, 97.0%, 5g

N,N'-(Methylenebis(4,1-phenylene))bis(2,2-dimethylhydrazinecarboxamide), 97.0%, 10g

2-((1R,4R)-4-(4-(4-Amino-7,7-dimethyl-7H-pyrimido[4,5-b][1,4]oxazin-6-yl)phenyl)cyclohexyl)acetic acid, 95.0%, 5mg

(4-Butoxy-2,3-difluorophenyl)boronic acid, 95.0%, 5g

(6-Bromopyridin-3-yl)methanamine, 95.0%, 100g

N-(2-Chloro-benzyl)-cyclohexane-1,4-diamine hydrochloride, 95.0%, 250mg

2,4-Dihydroxy-3-methoxybenzaldehyde, 97%, 1g

Phase contrast slide with phasing for PLPH 10x and S40x plan phase objectives

N-(4-Cyanophenyl)acetamide, 95.0%, 5g

4,5-Dichloropyridin-2(1H)-one, 97.0%, 100mg